Topic: JAK inhibitors

Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.

Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.

The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.

The results position the potential blockbuster to advance into phase 3 in ankylosing spondylitis, although a safety signal gave investors a scare.

Gilead paid billions to get into the CAR-T game with its purchase of Kite Pharma, and now it's looking to offload some unwanted cancer assets.

Gilead is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib that could be an antidote for the biotech’s hepatitis C hangover.

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib may be scuppered again by FDA concerns on safety.

Theravance will bring its GI drug through phase 2/3 in Crohn's disease and ulcerative colitis.

On the first day of the big biotech conference that is J.P. Morgan, Celgene has come right out on day one with M&A news.

Galapagos has taken up its option to co-promote filgotinib with Gilead in certain European nations, but Gilead will be free to acquire its partner in two weeks.